ArticleAngewandte Chemie (International ed. in English)2015
Fragment-Based De Novo Design Reveals a Small-Molecule Inhibitor of Helicobacter Pylori HtrA.
Article in Angewandte Chemie (International ed. in English), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Beyond Urease: New Potential Enzymatic Targets inACS omega · 2026Review
- Predicting clinical outcomes in Helicobacter pylori-positive patients using supervised learning through the integration of demographic and genomic features.BMC gastroenterology · 2026Article
- The gram-positive HtrA, the protease that is also a chaperone.Journal of bacteriology · 2026Review
- The serine protease HtrA regulates Group B Streptococcus virulence and affects the host response to infection.PLoS pathogens · 2025Article
- Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors.The protein journal · 2023Article
- Trimer stability of Helicobacter pylori HtrA is regulated by a natural mutation in the protease domain.Medical microbiology and immunology · 2023Article
- Molecular Targets inBiomolecules · 2023Review
- Evolution and Role of Proteases inBiomolecules · 2023Review
- Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 againstPharmaceutics · 2022Article
- Function, molecular mechanisms, and therapeutic potential of bacterial HtrA proteins: An evolving view.Computational and structural biotechnology journal · 2022Review
- Campylobacter Virulence Factors and Molecular Host-Pathogen Interactions.Current topics in microbiology and immunology · 2021Review
- Review
- The proteolytic activity of Listeria monocytogenes HtrA.BMC microbiology · 2019Article
- The unique trimeric assembly of the virulence factor HtrA fromThe Journal of biological chemistry · 2019Article
- Computational advances in combating colloidal aggregation in drug discovery.Nature chemistry · 2019Review
- Quantification of serine protease HtrA molecules secreted by the foodborne pathogenGut pathogens · 2019Article
- Function of Serine Protease HtrA in the Lifecycle of the Foodborne PathogenEuropean journal of microbiology & immunology · 2018Review
- Mercaptoacetate thioesters and their hydrolysate mercaptoacetic acids jointly inhibit metallo-β-lactamase L1.MedChemComm · 2018Article
- Review
- Bacterial serine protease HtrA as a promising new target for antimicrobial therapy?Cell communication and signaling : CCS · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
Abstract
Sustained identification of innovative chemical entities is key for the success of chemical biology and drug discovery. We report the fragment-based, computer-assisted de novo design of a small molecule inhibiting Helicobacter pylori HtrA protease. Molecular binding of the designed compound to HtrA was confirmed through biophysical methods, supporting its functional activity in vitro. Hit expansion led to the identification of the currently best-in-class HtrA inhibitor. The results obtained reinforce the validity of ligand-based de novo design and binding-kinetics-guided optimization for the efficient discovery of pioneering lead structures and prototyping drug-like chemical probes with tailored bioactivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.